Kyverna Therapeutics股票讨论

$Kyverna Therapeutics (KYTX.US)$
Kyverna Therapeutics宣布了新的患者数据，突出KYV-101在ACR Convergence 2024研讨会上治疗狼疮肾炎的潜力
Kyverna Therapeutics为KYV-101更新的临床数据进行了介绍，这是他们针对狼疮肾炎（LN）治疗的CD19 CAR T细胞疗法。数据显示，在接受目标剂量为1×10^8 CD19 CAR T细胞治疗的患者中，有四名患者至少有六个月的随访，表现出持久的疗效和耐受性。关键发现展示了深度B细胞耗竭，免疫系统重置，稳定的eGFR，保持的肾功能以及改善的SLE活动。该治疗允许消除免疫抑制剂并减少糖皮质激素的使用，同时保持了可管理的安全性格局，并未观察到高级别的CRS或ICANS。

$Kyverna Therapeutics (KYTX.US)$
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...